$HIMS news
The latest HIMS stock news: headlines, filings, AI summaries and sentiment for $HIMS, updated around the clock.
- Hims & Hers Q3 Results Show Margin Contraction and Subscriber Decline
- CNBC Investing Club Downgrades Nvidia and Discusses Macroeconomic Shifts
- Hims & Hers Health Shares Drop 14% Following Earnings Miss and Lowered Guidance
- Hims & Hers Health Announces November Launch of Peptides+ Product Category
- Hims & Hers Reports Q3 2026 Revenue Growth Amid Strategic Marketing Pullback
- Pre-market Stock Movers: Sanmina, Take-Two Interactive, and Securitize Gain on Strong Results
- Hims & Hers Reports 49% Revenue Growth in Q3 2026 Amid International Expansion
- Hims & Hers Projects Q4 Revenue Between $875M and $895M Amid GLP-1 Expansion
- Hims & Hers Health Shares Fall After Q3 Earnings Miss and Lowered 2026 Guidance
- Hims & Hers Health, Inc. - 10-Q Filing
- Hims & Hers Health Reports Q3 2026 Results with Revenue and EPS Misses
- Hims & Hers Health, Inc. - 8-K Filing
- Hims & Hers Health, Inc. - 8-K Filing
- Hims & Hers Health (HIMS) Scheduled to Report Q3 Earnings on November 9
- Market Outlook: Strong Jobs Data, Tech Volatility, and Key Earnings Results
- Hims & Hers Health Shares Rise Following HHS Announcement on Peptide Compounding
- Class Action Lawsuit Filed Against Hims & Hers Health Following FTC Allegations
- Class Action Lawsuit Filed Against Hims & Hers Health, Inc.
- Hims & Hers Health Appoints Jon Franklin as New Chief Accounting Officer
- Hims & Hers Health, Inc. - 8-K Filing
- Class Action Lawsuit Filed Against Hims & Hers Health, Inc.
- Hims & Hers Posts Negative Reported EBITDA for Two Consecutive Quarters Amid Margin Declines
- Hims & Hers Chief Legal Officer Sells Shares Under Pre-Set Trading Plan
- Hims & Hers Chief Legal Officer Sells Shares Under Pre-Set Trading Plan
- JP Morgan Resumes Coverage of Hims & Hers Health with Neutral Rating Amid GLP-1 Compounding Challenges
- Tech Executives' Pay Surpasses C-Suite Peers Amid AI Expansion
- Hims & Hers CEO Disputes FTC's Understanding of Company Practices
- Hims & Hers Faces Penalties from Visa Over Credit Card Disputes
- Blackbird Closes Record A$1.05 Billion Fund VI to Support VC Founders
- Stocks Making Significant Moves Midday: Expedia, Nvidia, Hims & Hers Among Others
- Hims & Hers CEO Sells Shares in Routine Tax Withholding Transaction
- Hims & Hers CTO Sells $2.7 Million in Stock for Tax Withholding
- Hims & Hers CFO Disposes of Over $3 Million in Stock
- Hims & Hers' Chief Policy Officer Files Insider Transaction
- Hims & Hers CMO Sells Shares Amid Expansion into Testosterone and Peptides
- Hims Insider Filing Shows Tax-Related Share Sale by COO
- Hims & Hers CLO Files SEC Form 4 Filing Showing Share Sale
- Hims & Hers' Chief Accounting Officer Is Leaving
- Hims & Hers Health Faces FTC Allegations Amid Slowing Growth
- Short Interest Data Reveals Investor Sentiment Divide Among Healthcare Stocks
- FTC Lawsuit Targets Hims & Hers Business Practices, Impacting Stock
- FTC Files Lawsuit Against Hims & Hers Over Health Data Sharing and Billing Practices
- FTC Sues Hims & Hers for Allegedly Sharing Patient Data with Advertisers Meta and Snap
- FTC Sues Hims & Hers Over Data Sharing and Billing Practices
- US FTC Sues Hims & Hers for Sharing User Health Data with Meta and Snap
- FTC Files Lawsuit Against Hims & Hers Health
- FDA Panel Recommends Four Peptides for Inclusion on Compounding List
- Hims & Hers Stock Drops After FDA Panel Rejects Emideltide Inclusion
- FDA Advisory Panel Rejects Peptide Restriction Loosening, Hims & Hers Shares Drop
- FDA Panel Endorses BPC-157, Boosting Hims & Hers Health (HIMS)